You are here: Industry Insights > FRESENIUS

News List

Fresenius pulls out of $4.3bn Akorn merger pharmatimes
July 16, 2018
German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions.
Vifor Fresenius snap up rights to Cara’s itch therapy pharmafile
May 25, 2018
The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva.
Fresenius Terminates $4.3-Billion Merger with Akron americanpharmaceuticalreview
May 18, 2018
Fresenius Kabi has decided to terminate the company’s previously announced merger agreement with Akorn, a United States-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products.
Fresenius alleges ‘blatant fraud at the very top level’ of Akorn operations fiercepharma
May 08, 2018
Fresenius continues to hammer Akorn with allegations of fraud in its drug development and manufacturing as the German company battles to extract itself from its $4.3 billion buyout of the U.S. sterile injectables maker...
Fresenius pulls out of $4.3bn Akorn merger pharmatimes
April 24, 2018
German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions.
Fresenius Medical Care gets recognition by ACHS biospectrumasia
March 16, 2018
Full accreditation against the ten National Safety and Quality in Healthcare Standards as well as the five EQuIPNational Standards was awarded by ACHS in December 2017.
Fresenius confirms takeover talks with Akorn pharmafile
April 10, 2017
Fresenius, Europe’s largest publicly traded healthcare provider, has engaged in discussions with Akorn, a pharmaceutical ...

Previous page 1 2 Next page